Ping Liu

US Patent:

20210395236, Dec 23, 2021

Filed:

Oct 25, 2019

Appl. No.:

17/286870

Inventors:

- Rahway NJ, US
William P. KAPLAN - Boston MA, US
Michael J. ARDOLINO - Arlington MA, US
Joanna L. CHEN - Braintree MA, US
Peter H. FULLER - Ashland MA, US
Hakan GUNAYDIN - Somerville MA, US
Derun LI - Roxbury MA, US
Ping LIU - Westfield NJ, US
Kaitlyn Marie LOGAN - Boston MA, US
Joey METHOT - Westwood MA, US
Gregori J. MORRIELLO - Randolph NJ, US
Santhosh F. NEELAMKAVIL - Edison NJ, US
Luis TORRES - Norwood MA, US
Xin YAN - Newton MA, US
Hua ZHOU - Acton MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 405/14
C07D 403/04
C07D 413/04
C07D 417/04
C07D 413/14
C07D 417/14
C07D 409/14
C07D 401/14

Abstract:

The present invention is directed to substituted certain N-heteroaryl indazole derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, X, Y, and Z are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.